CytomX Therapeutics Inc (CTMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $444.73M
Last updated: Nov 17, 2026 at 11:04 AM ET
CytomX Therapeutics Inc (CTMX) Stock Forecast
Analysts expect CytomX Therapeutics (CTMX) to earn -$0.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $21.96M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.63, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 37.5% |
| Buy | 5 | 62.5% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 36.5%.
- Fiscal year ending Dec 31, 2026
- -$0.39
- EPS consensus, revenue $21.96M
- Fiscal year ending Dec 31, 2027
- -$0.50
- EPS consensus, revenue $29.98M
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.39 | -$0.51 to -$0.33 | 7 | $21.96M | $11.95M to $31.30M | 6 |
| Dec 31, 2027 | -$0.50 | -$1.04 to -$0.17 | 7 | $29.98M | N/A | 5 |
Quarterly Estimates
The EPS consensus is -$0.10 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.10 | -$0.12 to -$0.06 | 10 | $5.75M | $1.96M to $10.50M | 8 |
| Mar 31, 2027 | -$0.10 | -$0.13 to -$0.05 | 5 | $5.08M | N/A | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.39 | -$0.39 | -$0.39 | -$0.39 | -$0.39 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.50 | -$0.47 | -$0.47 | -$0.47 | -$0.47 | N/A |
| Quarter ending Mar 31, 2027 | -$0.10 | -$0.13 | -$0.13 | -$0.13 | -$0.13 | N/A |
Frequently Asked Questions About CTMX
What is the CTMX stock forecast?
Consensus analyst estimates put CytomX Therapeutics's EPS at -$0.39 for the fiscal year ending Dec 31, 2026, on revenue of $21.96M. The consensus rating from 8 analysts is Buy.
How do analysts rate CTMX stock?
Of 8 analysts covering CytomX Therapeutics, 3 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CTMX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.39, with estimates from -$0.51 to -$0.33 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.50, with estimates from -$1.04 to -$0.17 from 7 analysts.
What revenue do analysts expect from CytomX Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $21.96M, with estimates from $11.95M to $31.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $29.98M.
How many analysts cover CTMX?
8 analysts rate CytomX Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CTMX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors